March 20th 2025
John Strasswimmer, MD, PhD, spoke on the difficulty of managing adverse effects, the role of interdisciplinary clinical relationships, and the challenges in complex and older patients.
Improvement Needed in Immediate Access to VA Skin Cancer Care in Midwest, East Coast
May 13th 2022In a presentation at the current American College of Mohs Surgery meeting, Jennifer G. Powers, MD, highlights the needed improvement for immediate access to skin cancer care for VA patients, noting a 33 day average wait time compared to the VAs optimal goal of 28 days.
Skin Cancer and the Cutaneous Microbiome: Thinking Small May Produce Big Results
April 13th 2022The human microbiota and its involvement in human health and disease has been emphasized in recent years. Now, researchers have begun to explore whether a patient’s unique microbiota may influence skin cancer risk and response to therapy.
The Science Behind Using Circulating Tumor DNA for MCC
March 31st 2022In this second part of a 4 part video series, Lisa Zaba, MD, PhD, FAAD, explains the data behind the clinical trials on using circulating tumor DNA for merkel cell carcinoma (MCC). She expands on her talk from the 2022 American Academy of Dermatology Annual Meeting.
The Utility of Circulating Tumor DNA for Detecting Clinically Evident and Occult MCC
March 30th 2022In this first part of a 4 part video series, Lisa Zaba, MD, PhD, FAAD, explains the science behind her presentation on "The Utility of Circulating Tumor DNA for Detecting Clinically Evident and Occult Merkel Cell Carcinoma." This was presented at the 2022 American Academy of Dermatology Annual Meeting.